A prominent research firm, Cognizance Market Research added a cutting-edge industry report on “Global Lungs Disease Therapeutics Market”. The report studies the current as well as past growth trends and opportunities for the market to gain valuable insights during the forecast period from 2022 to 2030.
Lungs Disease Therapeutics Market Analysis:
According to cognizance market research the Lungs Disease Therapeutics Market is expected to register a CAGR of 3.9% from 2022 to 2030.
What is Lungs Disease Therapeutics Market?
The term “lung disease therapeutics” refers to the variety of medical procedures and pharmacological items used to control and treat pulmonary diseases and disorders. These ailments include lung cancer, asthma, pulmonary fibrosis, cystic fibrosis, chronic obstructive pulmonary disease (COPD), and others. Depending on the individual problem and the severity of the sickness, many treatment options are available for these conditions.
Inhalers and nebulizers are frequently used to administer medicines directly to the lungs, providing asthma sufferers and those with other respiratory disorders with quick and efficient relief. Additionally, the use of oral drugs such as bronchodilators, corticosteroids, and antibiotics is utilised to treat symptoms and enhance the functioning of the lungs.
The pharmaceutical industry’s lung disease therapeutics market specialises in creating, manufacturing and dispensing pharmaceuticals and medical equipment for the diagnosis and treatment of respiratory illnesses. The illnesses included are lung cancer, pulmonary fibrosis, asthma and COPD. The market offers a range of goods, such as oral drugs, biologists, nebulisers, oxygen treatment equipment, and inhalers.
The rising frequency of respiratory disorders, particularly in older persons, is the main factor driving the market for treatment for lung diseases. The burden of respiratory disorders is increasing globally due to a number of causes, including an ageing population, raising pollution levels, and lifestyle choices including smoking and poor diets. Pharmaceutical companies are spending a lot of money on research and development to find novel and efficient medicines for this illness.
Innovations in medical technology and drug development which have resulted in the launch of novel and more effective therapies for respiratory disorders are also driving the market. However, some of the biggest difficulties faced by competitors in the lung diseases therapeutics market are regulatory obstacles, high research and the drawn-out approval procedure for new pharmaceutical and medical devices.
Lungs Disease Therapeutics Market Outlook:
In the upcoming years, the market for therapies for lung diseases is anticipated to expand at a steady rate thanks to a number of factors. The rising incidence of respiratory disorders, particularly in ageing populations, is one of the main contributors. The prevalence of respiratory disorders like COPD and asthma are rising along with air pollution levels and sedentary lifestyles.
The market for therapies for lung diseases is expanding as a result of developments in medical technology and drug discovery. The demand for these goods is been fuelled by the development of novel therapies and equipment, such as portable oxygen concentrators and biologics, which are improving outcomes for patients with respiratory disorders.
The market does face certain difficulties, though. Smaller firms may find it challenging to compete in the market due to regulatory obstacles and the high cost of drug development. Additionally, the COVID-19 pandemic has had a considerable influence on the market for treatments for lung diseases, causing delays in clinical studies and interruptions to supply chains.
The development of biologics, combination therapy, personalised medicines, digital health technologies, and growth potential in new regions are among the major trends and opportunities in the therapeutic market for lung diseases. These advancements aim to promote access to healthcare to people with respiratory disorders, individualise treatment techniques, and improve treatment efficacy. As new tools and therapies are created to address the rising burden of respiratory disorders, the market is anticipated to expand.
The lungs disease therapeutics market can be segmented by type of disease, type of therapy, and distribution channel.
By type of disease:
Asthma: A persistent respiratory condition called asthma results in inflammation and airway narrowing like wheezing, coughing and shortness of breath.
COPD (Chronic Obstructive Pulmonary Disease): Chronic bronchitis and emphysema are two of the lung disorders in the COPD category that progressively block airways and make breathing difficult.
Cystic Fibrosis: Mucus build up in the lungs and other organs as a result of the hereditary condition cystic fibrosis, which affects the digestive and respiratory systems.
Pulmonary Arterial Hypertension (PAH): A uncommon and progressive kind of high pressure that affects the arteries in the lungs is referred to as pulmonary arterial hypertension.
Idiopathic Pulmonary Fibrosis (IPF): It is a form of interstitial lung disease that results in lung tissue stiffening and scarring, making it difficult to breathe and impairing lung function.
Others: Lung cancer, bronchiectasis, and pulmonary embolism are examples of respiratory illnesses.
COPD is the leading sector because of its high incidence and an enormous burden on healthcare systems throughout the world. COPD is expected to be the third biggest cause of mortality globally by 2030, according to the World Health Organization.
By treatment type:
Bronchodilators are drugs that relax and enlarge the airways, making breathing easier. Bronchodilators, both short and long-acting, are included.
Corticosteroids are anti-inflammatory drugs that assist to relieve the symptoms of respiratory disorders by reducing swelling and inflammation in the airways.
Monoclonal antibodies are biological medications that target molecules in the immune system to treat respiratory disorders such as severe asthma and COPD.
Combination Therapy: the administration of two or more medications with distinct mechanisms of action in order to enhance symptom management and outcomes in patients with respiratory disorders.
Other options include oxygen therapy, pulmonary rehabilitation, and lung transplantation.
Bronchodilators are the market leader due to their extensive usage in the treatment of respiratory illnesses such as asthma and COPD.
By channel of distribution:
Hospital Pharmacies: These are pharmacies that are housed within hospitals and provide acute treatment and management of respiratory disorders.
Retail Pharmacies: typical brick-and-mortar pharmacies that provide customers with a convenient way to fill prescriptions and obtain over-the-counter respiratory treatments.
Online pharmacies are a rising market sector that provides patients with simple access to respiratory illness treatments as well as home delivery services.
Hospital pharmacies are the market leader due to their involvement in providing acute treatment and managing respiratory disorders.
It is important to note that these figures may differ based on the source and methodology utilised to gather and evaluate the data. However, these divisions can give useful insights into the dynamics of the lung disease treatments market and assist players in making educated decisions regarding product development, marketing, and distribution strategies.
Based on geography the Lungs Disease Therapeutics Market has been segmented into five main regions namely, North America, Asia Pacific, Europe, Latin America, and Middle East & Africa.
Because of the high frequency of respiratory disorders, well-established healthcare infrastructure, and high healthcare spending, North America is the largest market for lung disease therapies. Major companies in this region, such as GlaxoSmithKline, AstraZeneca, and Boehringer Ingelheim, also contribute to market growth.
Due to the high incidence of respiratory disorders, good reimbursement policies, and rising use of sophisticated medicines, Europe is the second biggest market for lungs disease therapeutics. The existence of significant companies such as Novartis, Teva Pharmaceutical Industries Ltd., and Chiesi Farmaceutici S.p.A. also drives the industry.
Because of the increasing frequency of respiratory illnesses, rising healthcare spending, and expanding demand for innovative medicines, the Asia-Pacific region is the fastest-growing market for lung disease therapeutics. The existence of large firms such as GlaxoSmithKline, Novartis, and AstraZeneca significantly drives the industry.
Other regions, such as Latin America, the Middle East, and Africa, are likely to have considerable growth as a result of increased respiratory illness prevalence and healthcare costs.
The report offers the revenue of the Lungs Disease Therapeutics Market for the period 2020-2030, considering 2020 & 2021 as a historical years, 2022 as the base year and 2023 to 2030 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the Lungs Disease Therapeutics Market for the forecast period. The Lungs Disease Therapeutics Market report provides insights and in-depth analysis into developments impacting enterprises and businesses on a regional and global level. The report covers the Lungs Disease Therapeutics Market performance in terms of revenue contribution from several segments and comprises a detailed analysis of key drivers, trends, restraints, and opportunities prompting revenue growth of the Lungs Disease Therapeutics Market.
The report has been prepared after wide-ranging secondary and primary research. Secondary research included internet sources, numerical data from government organizations, trade associations, and websites. Analysts have also employed an amalgamation of bottom-up and top-down approaches to study numerous phenomena in the Lungs Disease Therapeutics Market. Secondary research involved a detailed analysis of significant players’ product portfolio. Literature review, press releases, annual reports, white paper, and relevant documents have been also studied to understand the Lungs Disease Therapeutics Market. Primary research involved a great extent of research efforts, wherein experts carried out interviews telephonic as well as questioner-based with industry experts and opinion-makers.
The report includes an executive summary, along with a growth pattern of different segmented included in the scope of the study. The Y-o-Y analysis with elaborate market insights has been provided in the report to comprehend the Y-o-Y trends in the Lungs Disease Therapeutics Market. Additionally, the report focuses on altering competitive dynamics in the global market. These indices serve as valued tools for present market players as well as for companies interested in participating in the Lungs Disease Therapeutics Market. The subsequent section of the Lungs Disease Therapeutics Market report highlights the USPs, which include key industry events (Type launch, research partnership, acquisition, etc.), technology advancements, pipeline analysis, prevalence data, and regulatory scenario.
Lungs Disease Therapeutics Market Competitive Landscape:
The lungs disease therapeutics market is highly competitive, with a large number of companies operating in the space. Some of the leading companies in the market include:
AstraZeneca plc and Amgen, Inc. have announced a cooperation to develop and market an asthma and chronic obstructive pulmonary disease therapy (COPD). Tezepelumab, a possible first-in-class drug that addresses the underlying causes of severe respiratory disorders, will be developed and commercialised collaboratively by the two firms.
In another development, Boehringer Ingelheim International GmbH announced the release of Spiolto Respimat, a novel COPD inhaler device. To promote symptom alleviation and lung function, the gadget contains two active substances, tiotropium and olodaterol.
The report explores the competitive scenario of the Lungs Disease Therapeutics Market. Major players working in the Lungs Disease Therapeutics Market have been named and profiled for unique commercial attributes. Company overview (company description, Type portfolio, geographic presence, employee strength, Key management, etc.), financials, SWOT analysis, recent developments, and key strategies are some of the features of companies profiled in the Lungs Disease Therapeutics Market report.
Global Lungs Disease Therapeutics Market, By Type of Disease:
Global Lungs Disease Therapeutics Market, By Type of Therapy:
Global Lungs Disease Therapeutics Market, By Distribution Channel:
Global Lungs Disease Therapeutics Market, by Region:
The global lungs disease therapeutics market is a segment of the pharmaceutical industry that specializes in the development, manufacturing, and distribution of pharmaceuticals and medical devices for the diagnosis and treatment of respiratory diseases. These diseases include lung cancer, pulmonary fibrosis, asthma, and chronic obstructive pulmonary disease (COPD). The market offers a range of products, such as oral drugs, biologics, nebulizers, oxygen treatment equipment, and inhalers.
The key drivers of growth in the global lungs disease therapeutics market include:
The key challenges facing the global lungs disease therapeutics market include:
North America is currently the largest market for lungs disease therapeutics, due to the high frequency of respiratory disorders, well-established healthcare infrastructure, and high healthcare spending. However, the Asia-Pacific region is expected to grow at the fastest rate in the coming years, due to the increasing frequency of respiratory illnesses, rising healthcare spending, and expanding demand for innovative medicines.
The opportunities for market players in the global lungs disease therapeutics market include:
Lungs Disease Therapeutics Market
Don’t Miss Out On The Biggest Savings Of The Year!
Get insights that lead to new growth opportunities
We can customize every report – free of charge – including purchasing stand-alone sections or country-level reports
We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail